INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
![Foto de INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA](/img/noimage.png)
![Foto de Università di Perugia](/img/noimage_org.png)
Università di Perugia
Perugia, ItaliaPublicaciones en colaboración con investigadores/as de Università di Perugia (33)
2023
2022
-
Guiding the global evolution of cytogenetic testing for hematologic malignancies
Blood, Vol. 139, Núm. 15, pp. 2273-2284
-
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
The Lancet Haematology, Vol. 9, Núm. 2, pp. e98-e110
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253
2021
-
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798
-
Expanding the genetic spectrum of TUBB1-related thrombocytopenia
Blood Advances, Vol. 5, Núm. 24, pp. 5453-5467
-
GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis
Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 10, pp. 2612-2617
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2020
-
A reference map of the human binary protein interactome
Nature, Vol. 580, Núm. 7803, pp. 402-408
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
2019
-
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients
Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106
-
The Big Data Sjögren consortium: A project for a new data science era
Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23
2018
-
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)
Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111
-
Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis
JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397
2017
-
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
British Journal of Haematology, Vol. 178, Núm. 4, pp. 571-582
2016
2014
-
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362
-
Research update for articles published in EJCI in 2012
European Journal of Clinical Investigation, Vol. 44, Núm. 10, pp. 1010-1023
2013
-
Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials
Haematologica, Vol. 98, Núm. 6, pp. 980-987